Crinetics Pharmaceuticals (CRNX) Operating Income (2017 - 2026)
Crinetics Pharmaceuticals' quarterly Operating Income came in at -$140.4 million in Q1 2026, down 26.01% year-on-year from -$189.7 million in Q1 2025, and down 5.02% quarter-over-quarter from -$133.7 million in Q4 2025.
Crinetics Pharmaceuticals has reported Operating Income for 10 years, with the latest figure at -$140.4 million in Q1 2026.
- For the quarter ending Q1 2026, Operating Income fell 26.01% year-over-year to -$140.4 million; the trailing twelve-month figure through Mar 2026 stood at -$545.7 million (down 44.86% YoY), and the FY2025 full-year result was -$516.8 million, down 52.5% from the prior year.
- Operating Income for Q1 2026 stood at -$140.4 million, down from -$133.7 million in the prior quarter.
- The five-year high for Operating Income was -$33.8 million in Q1 2022, with the low at -$142.6 million in Q3 2025.
- Average Operating Income over 5 years is -$81.6 million, with a median of -$73.5 million recorded in 2024.
- Year-over-year, Operating Income tumbled 64.99% in 2022 and declined 23.12% in 2023.
- Tracing CRNX's Operating Income over 5 years: stood at -$47.6 million in 2022, then plunged by 31.76% to -$62.7 million in 2023, then plunged by 51.21% to -$94.7 million in 2024, then plunged by 41.08% to -$133.7 million in 2025, then declined by 5.02% to -$140.4 million in 2026.
- The last three Operating Income figures came in at -$140.4 million (Q1 2026), -$133.7 million (Q4 2025), and -$142.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.97 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -15.76 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 642.90 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 268.64 Mn |
| 10 | Crinetics Pharmaceuticals | 3.59 Bn | 3.59 Bn | 10.53 Mn | -140.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -140.38 Mn |
| Dec 31, 2025 | -133.67 Mn |
| Sep 30, 2025 | -142.59 Mn |
| Jun 30, 2025 | -129.11 Mn |
| Mar 31, 2025 | -111.41 Mn |
| Dec 31, 2024 | -94.75 Mn |
| Sep 30, 2024 | -87.80 Mn |
| Jun 30, 2024 | -82.78 Mn |
| Mar 31, 2024 | -73.53 Mn |
| Dec 31, 2023 | -62.66 Mn |
| Sep 30, 2023 | -58.98 Mn |
| Jun 30, 2023 | -53.00 Mn |
| Mar 31, 2023 | -47.98 Mn |
| Dec 31, 2022 | -47.56 Mn |
| Sep 30, 2022 | -43.45 Mn |
| Jun 30, 2022 | -43.05 Mn |
| Mar 31, 2022 | -33.83 Mn |
| Dec 31, 2021 | -30.89 Mn |
| Sep 30, 2021 | -27.81 Mn |
| Jun 30, 2021 | -26.09 Mn |
| Mar 31, 2021 | -22.92 Mn |
| Dec 31, 2020 | -21.79 Mn |
| Sep 30, 2020 | -18.45 Mn |
| Jun 30, 2020 | -16.93 Mn |
| Mar 31, 2020 | -17.78 Mn |
| Dec 31, 2019 | -15.21 Mn |
| Sep 30, 2019 | -15.23 Mn |
| Jun 30, 2019 | -13.35 Mn |
| Mar 31, 2019 | -10.04 Mn |
| Dec 31, 2018 | -9.43 Mn |
| Sep 30, 2018 | -8.07 Mn |
| Jun 30, 2018 | -5.68 Mn |
| Mar 31, 2018 | -5.53 Mn |
| Dec 31, 2017 | -2.50 Mn |
| Sep 30, 2017 | -2.37 Mn |
| Jun 30, 2017 | -1.64 Mn |